DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

About DelMar Pharmaceuticals

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DMPI
  • CUSIP:
Key Metrics:
  • Previous Close: $4.95
  • 50 Day Moving Average: $4.16
  • 200 Day Moving Average: $5.00
  • 52-Week Range: $2.88 - $10.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.36
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 0.92
  • Return on Assets: -155.84%
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Additional Links:
Companies Related to DelMar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for DelMar Pharmaceuticals (NASDAQ:DMPI) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (114.29% upside)

Analysts' Ratings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateFirmActionRatingPrice TargetDetails
1/26/2017Maxim GroupReiterated RatingBuy$11.00View Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00View Rating Details
9/12/2016HC WainwrightReiterated RatingBuy$12.00View Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyView Rating Details
(Data available from 2/22/2015 forward)


Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/13/2016($0.05)($0.03)ViewN/AView Earnings Details
5/18/2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015($0.06)($0.03)ViewN/AView Earnings Details
11/11/2014($0.07)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for DelMar Pharmaceuticals (NASDAQ:DMPI)
Current Year EPS Consensus Estimate: $-0.80 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.27)($0.19)($0.23)
Q3 20172($0.28)($0.20)($0.24)
Q4 20172($0.55)($0.43)($0.49)
(Data provided by Zacks Investment Research)


Dividend History for DelMar Pharmaceuticals (NASDAQ:DMPI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership Percentage: 1.69%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.00View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateHeadline logoDELMAR PHARMACEUTICALS, INC. Financials (NASDAQ:DMPI) - February 16 at 2:46 PM logoDelmar Pharma (DMPI) Doses First Patient in Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM (NASDAQ:DMPI) - February 13 at 5:29 PM logoDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results (NASDAQ:DMPI) - February 13 at 5:28 PM logoDelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) (NASDAQ:DMPI) - February 13 at 5:28 PM logoDelMar Pharmaceuticals Inc. (NASDAQ:DMPI) Moves Forward With Flagship Chemotherapy Into Phase II (NASDAQ:DMPI) - February 6 at 4:48 PM logoDelMar Pharmaceuticals, Inc. - "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson" (NASDAQ:DMPI) - January 30 at 10:43 AM logoDelmar Pharma (DMPI), MD Anderson Initiate New Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM (NASDAQ:DMPI) - January 26 at 3:58 AM logoDelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) (NASDAQ:DMPI) - January 25 at 5:57 PM
News IconNew Analyst Ratings On Canadian Energy (CESDF) (NASDAQ:DMPI) - January 18 at 5:07 PM logoThe Nasdaq notched a fresh record while the S&P 500 rose 0.2% to 2,274.58 (NASDAQ:DMPI) - January 13 at 5:31 PM logoDelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 (NASDAQ:DMPI) - January 9 at 4:37 PM logoAnalyst Activity – Aegis Initiates Coverage On DelMar Pharmaceuticals (NASDAQ:DMPI) With a Buy (NASDAQ:DMPI) - January 5 at 5:31 PM logoDelMar Pharmaceuticals : Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 (NASDAQ:DMPI) - December 21 at 5:31 PM logoDelMar Pharmaceuticals, Inc. - "21st Century Cures Act - A Holiday Gift for New Research in the Fight Against Cancer and Other Serious Diseases" (NASDAQ:DMPI) - December 20 at 9:50 AM logoDelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 (NASDAQ:DMPI) - December 14 at 5:48 PM logo8:12 am DelMar Pharma receives a Notice of Allowance from the USPTO for patent entitled, 'Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol' (NASDAQ:DMPI) - December 14 at 5:48 PM logoACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors (NASDAQ:DMPI) - December 13 at 10:27 PM logoNeuroGenetic Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Market Report (NASDAQ:DMPI) - December 8 at 5:28 PM logoLupin gains with USFDA approval for generic Topicort Ointment for US arm (NASDAQ:DMPI) - December 8 at 5:28 PM logoDMPI: Three New Clinical Trials with VAL-083 will be Initiated (NASDAQ:DMPI) - November 29 at 5:42 PM logoDelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting (NASDAQ:DMPI) - November 24 at 8:56 AM logoDelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme (NASDAQ:DMPI) - May 25 at 8:00 AM logoDelMar Pharmaceuticals, Inc. - "Reverse Stock Splits & Uplisting" (NASDAQ:DMPI) - May 19 at 10:32 AM logoDelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting (NASDAQ:DMPI) - May 19 at 10:16 AM logoDelMar Pharmaceuticals, Inc. - "60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology" (NASDAQ:DMPI) - May 16 at 10:21 AM logoDelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update (NASDAQ:DMPI) - May 13 at 8:00 AM logoFDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer (NASDAQ:DMPI) - April 21 at 8:00 AM logoSeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) Highlighting Partnership with MD Anderson (NASDAQ:DMPI) - April 14 at 9:00 AM
News IconDelMar (DMPI) Finds Opportunities in Abandoned Drugs (NASDAQ:DMPI) - April 5 at 1:22 PM logoBooming Orphan Drug Market Provides Investors with Massive Return Prospects (NASDAQ:DMPI) - March 30 at 7:00 AM
News IconDelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma (NASDAQ:DMPI) - March 15 at 11:38 AM logo8:31 am DelMar Pharma confirms FDA grants second Orphan Designation for VAL-083 in the treatment of medulloblastoma (see March 14 comment) (NASDAQ:DMPI) - March 15 at 8:31 AM logoFDA Grants Second Orphan Designation For VAL-083 (NASDAQ:DMPI) - March 15 at 8:30 AM logoDelMar Pharmaceuticals, Inc. - "GBM After Rintegra(R)" (NASDAQ:DMPI) - March 11 at 8:40 AM logo5 Top NASDAQ Biotech Stocks: Cardica Up 47 Percent (NASDAQ:DMPI) - March 1 at 2:03 PM logoRespireRx to Start Phase 2A Clinical Trial for CX1739 (NASDAQ:DMPI) - February 29 at 1:52 PM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events (NASDAQ:DMPI) - February 18 at 10:57 AM logoDMPI: Ready to Initiate Registration Phase II/III Trial (NASDAQ:DMPI) - February 18 at 10:00 AM logoCuris, Inc. : 4 Stocks to Consider for a Biotech Turnaround (NASDAQ:DMPI) - February 17 at 12:17 PM logo4 Stocks to Consider for a Biotech Turnaround (NASDAQ:DMPI) - February 17 at 11:55 AM logoEARNINGS SUMMARY: Details of DelMar Pharmaceuticals Inc. Q2 Earnings Report (NASDAQ:DMPI) - February 16 at 12:17 PM logoDelMar Pharmaceuticals Inc. Bottom Line Rises 327% In Q2 (NASDAQ:DMPI) - February 16 at 12:17 PM logoDelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update (NASDAQ:DMPI) - February 16 at 7:35 AM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:DMPI) - February 12 at 4:25 PM logoDelMar Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 (NASDAQ:DMPI) - February 4 at 7:35 AM logoMicroCap Review Magazine Winter/Spring 2016 Issue Now Available (NASDAQ:DMPI) - January 19 at 8:00 AM logoDMPI: DelMar Presents Positive Data from VAL-083 Phase II Expansion Clinical Trial in Refractory Glioblastoma Multiforme (NASDAQ:DMPI) - November 24 at 12:20 PM logoMaxim Group Reiterates BUY Rating for DelMar Pharmaceuticals, Inc. and Provides Company Update (NASDAQ:DMPI) - November 24 at 11:41 AM logoDelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting (NASDAQ:DMPI) - November 23 at 8:05 AM logoDelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015 (NASDAQ:DMPI) - November 19 at 8:05 AM


What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split on the morning of Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Where is DelMar Pharmaceuticals' stock going? Where will DelMar Pharmaceuticals' stock price be in 2017?

4 analysts have issued 1-year price targets for DelMar Pharmaceuticals' stock. Their predictions range from $3.00 to $16.00. On average, they expect DelMar Pharmaceuticals' stock price to reach $10.50 in the next twelve months.

When will DelMar Pharmaceuticals announce their earnings?

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 17th 2017.

How do I buy DelMar Pharmaceuticals stock?

Shares of DelMar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of DelMar Pharmaceuticals stock cost?

One share of DelMar Pharmaceuticals stock can currently be purchased for approximately $4.90.

DelMar Pharmaceuticals (NASDAQ:DMPI) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Earnings History Chart

Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Dividend History Chart

Dividend Payments by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)

Last Updated on 2/22/2017 by Staff